LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy (LOTTO-CRT)
Left Bundle Branch Pacing + Coronary Sinus Pacing Versus Left Bundle Branch Pacing Alone for Cardiac Resynchronization Therapy in Patients Eligible for CRT-P A Randomized Crossover Pilot Clinical Trial
The purpose of this pilot clinical trial is to evaluate whether a novel cardiac resynchronization strategy, called LOT-CRT, is more effective than standard physiological pacing alone (LBBAP) in patients with heart failure.
This is a randomized, single-center, crossover pilot study involving 10 patients. All participants will receive a specialized pacemaker (CRT-P) with leads implanted in two specific areas: the Left Bundle Branch Area (LBBAP) and the Coronary Sinus (CS).
Because of the crossover design, each patient will serve as their own control, receiving two different pacing configurations in a random order: Active Phase (LOT-CRT): Simultaneous pacing of the left bundle branch and the coronary sinus. Control Phase (LBBAP alone): Pacing only the left bundle branch area. Each treatment phase will last 6 months, for a total follow-up of 12 months per patient.
By testing both strategies in the same patient, this study will help clinicians identify the most effective way to restore heart synchrony and improve clinical outcomes in patients with advanced heart failure and conduction delays.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a single-center, randomized, crossover pilot clinical trial. Each patient will serve as their own control. Following the successful implantation of a device capable of stimulating the LBBAP and the coronary sinus, participants will be randomly assigned to one of two treatment sequences:
Sequence A: LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone Sequence B: LBBAP alone for 6 months, followed by LOT-CRT Each treatment phase will last 6 months, followed by an end-point evaluation and a crossover. Since the hemodynamic effect of electrical stimulation is immediate, no washout period is required between phases.
This study was designed as an exploratory pilot study; therefore, no formal sample size calculation was performed. The number of patients enrolled is considered adequate to assess the feasibility of the procedure, the safety of the crossover design, and to identify preliminary signals of clinical and electrical efficacy.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Antioquia
-
Medellín, Antioquia, 콜롬비아, 050036
- Clinica CardioVID
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥18 years
- Standard CRT-P indications according to ESC 2021 (EF ≤50%, QRS ≥130 ms, sinus rhythm or controlled AF)
- NYHA class II-IV
- Coronary venous anatomy suitable for placement of a coronary sinus electrode.
- Signed informed consent.
- Successful implantation of electrodes in the coronary sinus and in the left bundle branch area (LBBAP)
Exclusion Criteria:
- Concomitant indication for implantation of an implantable cardioverter-defibrillator (ICD) or CRT-D
- Significant uncorrected valvular disease or scheduled or anticipated cardiac surgery during the study period.
- Anatomical or technical contraindication for lead implantation in the coronary sinus or for lead implantation in the coronary sinus (such as sinus stenosis, coronary sinus branches unsuitable for cannulation, inability to advance and/or stabilize the lead, among others)
- Persistent atrial fibrillation with uncontrolled rate
- Comorbidities that may limit life expectancy to <1 year
- Participation in another clinical trial that could confound the evaluation of results within the last 6 months.
- Pregnancy or inadequate contraception
- In the researcher's opinion, the participant would not comply with the activities and visits outlined in the study protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Sequence A
LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone
|
The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing. The configuration for each phase of the study (LOT-CRT or LBBAP alone) will be assigned during randomization.
다른 이름들:
The LBBAP lead will be implanted via a transvenous approach using the C315His sheath, targeting the left bundle branch area in the right ventricular septum, ideally between the basal septum and the mid-septal region. Criteria for confirming successful LBBAP capture will include:
다른 이름들:
|
|
활성 비교기: Sequence B
LBBAP for 6 months only, followed by LOT-CRT
|
The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing. The configuration for each phase of the study (LOT-CRT or LBBAP alone) will be assigned during randomization.
다른 이름들:
The LBBAP lead will be implanted via a transvenous approach using the C315His sheath, targeting the left bundle branch area in the right ventricular septum, ideally between the basal septum and the mid-septal region. Criteria for confirming successful LBBAP capture will include:
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Compare the effects of the LOT-CRT strategy versus left bundle branch block pacing (LBBAP) alone in each patient, comparing baseline to the end of the study FEVI, quality of life and functional class by NYHA.
기간: 12 months
|
Investigators will evaluate the following parameters in each patient: Left ventricular ejection fraction (LVEF) by echocardiography and electrocardiogram; functional capacity (NYHA class) using the 6-minute walk test and symptoms reported by the patient; quality of life (MLHFQ) using the MLHFQ quality of life scale
|
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in end-systolic diameter
기간: 12 months
|
Absolute (mm) and relative (%) change in LVESV between baseline and 6 months.
|
12 months
|
|
QRS Duration
기간: 12 months
|
Absolute (ms) and relative (%) changes in the 12-lead ECG.
|
12 months
|
|
Change in end-diastolic diameter
기간: 12 months
|
Absolute (mm) and relative (%) change in LVEDV between baseline and 6 months.
|
12 months
|
|
NT-proBNP
기간: 12 months
|
Absolute (ng/mL) and relative (%) change in NT-proBNP from baseline to 6 months
|
12 months
|
|
Echocardiographic responder
기간: 12 months
|
LVEF ≥10% elevation or LVESV ≥15% decreased
|
12 months
|
|
Echocardiographic super-responder
기간: 12 months
|
LVEF ≥50% or LVESV ≥30% decrease
|
12 months
|
|
Composite Clinical Outcome
기간: 12 months
|
Cardiovascular Death or Hospitalization for Heart Failure
|
12 months
|
|
Procedural parameters
기간: 12 months
|
Thresholds, P- and R-waves, impedance of each electrode.
|
12 months
|
|
Procedure Time/Fluoroscopy
기간: 12 months
|
Total procedure time in minutes/ total fluoroscopy time in minutes.
|
12 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Juan F Agudelo, Electrophysiologist, Clinica CardioVID
- 연구 책임자: Susana Rios, Medical Epidemiologist, Clinica CardioVID
간행물 및 유용한 링크
일반 간행물
- Su L, Wang S, Wu S, Xu L, Huang Z, Chen X, Zheng R, Jiang L, Ellenbogen KA, Whinnett ZI, Huang W. Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study. Circ Arrhythm Electrophysiol. 2021 Feb;14(2):e009261. doi: 10.1161/CIRCEP.120.009261. Epub 2021 Jan 9.
- Herweg B, Welter-Frost A, Vijayaraman P. The evolution of cardiac resynchronization therapy and an introduction to conduction system pacing: a conceptual review. Europace. 2021 Apr 6;23(4):496-510. doi: 10.1093/europace/euaa264.
- Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, Birgersdotter-Green UM, Cha YM, Chung EH, Cronin EM, Curtis AB, Cygankiewicz I, Dandamudi G, Dubin AM, Ensch DP, Glotzer TV, Gold MR, Goldberger ZD, Gopinathannair R, Gorodeski EZ, Gutierrez A, Guzman JC, Huang W, Imrey PB, Indik JH, Karim S, Karpawich PP, Khaykin Y, Kiehl EL, Kron J, Kutyifa V, Link MS, Marine JE, Mullens W, Park SJ, Parkash R, Patete MF, Pathak RK, Perona CA, Rickard J, Schoenfeld MH, Seow SC, Shen WK, Shoda M, Singh JP, Slotwiner DJ, Sridhar ARM, Srivatsa UN, Stecker EC, Tanawuttiwat T, Tang WHW, Tapias CA, Tracy CM, Upadhyay GA, Varma N, Vernooy K, Vijayaraman P, Worsnick SA, Zareba W, Zeitler EP. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023 Sep;20(9):e17-e91. doi: 10.1016/j.hrthm.2023.03.1538. Epub 2023 May 20.
- Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available.
- Sieniewicz BJ, Gould J, Porter B, Sidhu BS, Teall T, Webb J, Carr-White G, Rinaldi CA. Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions. Heart Fail Rev. 2019 Jan;24(1):41-54. doi: 10.1007/s10741-018-9734-8.
- Burri H, Jastrzebski M, Cano O, Curila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023 Apr 15;25(4):1208-1236. doi: 10.1093/europace/euad043.
- Upadhyay GA, Jastrzebski M, Foley P, Chandrasekaran B, Whinnett Z, Schaller RD, Gardas R, Richardson T, Moskal P, Kudlik D, Stadler RW, Zimmerman P, Burrell J, Waxman R, Cornelussen RN, Lyne J, Herweg B, Vijayaraman P. Echocardiographic response from left bundle branch area pacing optimized cardiac resynchronization therapy (LOT-CRT) vs traditional CRT. Heart Rhythm. 2025 Oct;22(10):2616-2624. doi: 10.1016/j.hrthm.2025.04.026. Epub 2025 Apr 18.
- Chen X, Li X, Bai Y, Wang J, Qin S, Bai J, Wang W, Liang Y, Chen H, Su Y, Ge J. Electrical Resynchronization and Clinical Outcomes During Long-Term Follow-Up in Intraventricular Conduction Delay Patients Applied Left Bundle Branch Pacing-Optimized Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2023 Sep;16(9):e011761. doi: 10.1161/CIRCEP.122.011761. Epub 2023 Aug 14.
- Parale C, Bootla D, Jain A, Satheesh S, Anantharaj A, Ahmed AS, Sukumaran SK, Balaguru S, Selvaraj R. Comparison of electrocardiographic parameters between left bundle optimized cardiac resynchronization therapy (LOT-CRT) and left bundle branch pacing-cardiac resynchronization therapy (LBBP-CRT). Pacing Clin Electrophysiol. 2023 Aug;46(8):840-847. doi: 10.1111/pace.14793. Epub 2023 Jul 21.
- Jastrzebski M, Foley P, Chandrasekaran B, Whinnett Z, Vijayaraman P, Upadhyay GA, Schaller RD, Gardas R, Richardson T, Kudlik D, Stadler RW, Zimmerman P, Burrell J, Waxman R, Cornelussen RN, Lyne J, Herweg B. Multicenter Hemodynamic Assessment of the LOT-CRT Strategy: When Does Combining Left Bundle Branch Pacing and Coronary Venous Pacing Enhance Resynchronization?: Primary Results of the CSPOT Study. Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e013059. doi: 10.1161/CIRCEP.124.013059. Epub 2024 Oct 23.
- Vijayaraman P. Left Bundle Branch Pacing Optimized Cardiac Resynchronization Therapy: A Novel Approach. JACC Clin Electrophysiol. 2021 Aug;7(8):1076-1078. doi: 10.1016/j.jacep.2021.04.005. Epub 2021 Jul 28. No abstract available.
- Glikson M, Burri H, Abdin A, Cano O, Curila K, De Pooter J, Diaz JC, Drossart I, Huang W, Israel CW, Jastrzebski M, Joza J, Karvonen J, Keene D, Leclercq C, Mullens W, Pujol-Lopez M, Rao A, Vernooy K, Vijayaraman P, Zanon F, Michowitz Y, Nielsen JC, Boersma L, Blomstrom-Lundqvist C, Kronborg MB, Chung MK, Tse HF, Khan HR, Leyva F, Rojel-Martinez U, Rucinski M, Varma N. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace. 2025 Mar 28;27(4):euaf050. doi: 10.1093/europace/euaf050.
- Jastrzebski M, Moskal P, Huybrechts W, Curila K, Sreekumar P, Rademakers LM, Ponnusamy SS, Herweg B, Sharma PS, Bednarek A, Rajzer M, Vijayaraman P. Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group. Heart Rhythm. 2022 Jan;19(1):13-21. doi: 10.1016/j.hrthm.2021.07.057. Epub 2021 Jul 30.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- Clinica CardioVID
- ERP -2025-14209 (기타 보조금/기금 번호: Medtronic)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data, appropriately anonymized, that support the reported results will be made available to qualified researchers for the purposes of scientific research or meta-analysis. Requests must be addressed to the Principal Investigator and include a formal proposal. All requests will be subject to approval by the institutional ethics committee. As this is a study with a small sample size (10 patients), the protocol strictly enforces confidentiality; therefore, prior approval is always required to share these data.
The data will be available from 6 months to 5 years following the publication of the main results.
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .